摘要:
Compounds having the structure are peroxisome proliferator-activated receptor-gamma (PPAR-gamma) selective agonists and as such are useful in the modulation of blood glucose and the increase of insulin sensitivity in mammals. This activity of the piperazine derivatives of the invention make them particularly useful in the treatment of those conditions selected from the group consisting of diabetes, atherosclerosis, hyperglycemia, hyperlipidemia, obesity, syndrome X, insulin resistance, hypertension, heart failure and cardiovascular disease in mammals.
摘要:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
摘要:
The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.
摘要:
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
摘要:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
摘要:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
摘要:
Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
摘要:
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
摘要:
There are disclosed methods useful for the inhibition of inducible nitric oxide synthase by the adminstration of a compound of the formula I:. when R.sub.2 is H then R.sub.1 is selected from the group consisting of:1) aryl,--NH--C.sub.0 -C.sub.10 alkyl -aryl, N-(C.sub.0 -C.sub.10 alkyl substituted aryl).sub.2, --C.sub.0 -C.sub.10 alkyl substituted aryl, --N(C.sub.0 -C.sub.10 alkyl substituted aryl)(C.sub.0 -C.sub.10 alkyl), wherein "Aryl" is optionally attached to Compound I through C or N and is selected from the group consisting of isoindanolyl, isoindolinyl, tetrahydroquinolyl, phenyl, naphthyl, pyridyl, furyl, pyrryl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, triazolyl, tetrazolyl, pyrazinyl,pyrimidyl, quinolyl, isoquinolyl, benzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl, and benzoxazolyl; and the term "substituted aryl" denotes mono-, di- and/or tri-substituted aryl wherein aryl is as defined above and in which the substituents are independently selected from the group consistng of H, trifluoromethyl, amino, hydroxy, halo, nitro, --O--C.sub.1 -C.sub.6 alkyl, --S--C.sub.1 -C.sub.6 alkyl, --NH--C.sub.1 -C.sub.6 alkyl, --N (C.sub.1 -C.sub.6 allyl).sub.2, --C(O) --C.sub.1 -C.sub.6 alkyl, --NHC(O) C.sub.1 -C.sub.6 alkyl, --C.sub.1 -C.sub.11 COO.sub.2 R wherein R.dbd.C.sub.1 -C.sub.11 alkyl, or --C.sub.1 -C.sub.11 alkylphenyl, --C.sub.1 -C.sub.11 CONHR wherein R.dbd.C.sub.1 -C.sub.11 alkyl or C.sub.1 -C.sub.11 alkylphenyl, carboxy, --C(O) O C.sub.1 -C.sub.6 alkyl; trans-CH.dbd.CHCO.sub.2 R; wherein R.dbd.C.sub.1 -C.sub.11 alkyl or C.sub.1 -C.sub.6 alkylphenyl, trans CH.dbd.CHCONHR; wherein R.dbd.C.sub.1 -C.sub.11 alkyl or C.sub.1 -C.sub.11 alkylphenyl;2) cyclic --N(CH.sub.2 CH.sub.2).sub.2 Y, cyclic NCHA(CH.sub.2).sub.3, or --NH C.sub.2 -C.sub.11 alkyl-Y wherein A=i) C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 alkylaryl or,ii) COZR.sub.3 wherein Z=oxygen, NH and R.sub.3 =H, or C.sub.1 -C.sub.10 alkyl, or C.sub.0 -C.sub.10 alkylaryl wherein aryl group is as defined in (1) above, and Y=i) oxygen,or S, or NH orii) NC.sub.0 -C.sub.10 alkyl oriii) NC.sub.1 -C.sub.10 alkylsubstituted aryl,iv) NC=ZMR.sub.3 or COZR.sub.3 wherein Z=oxygen, or NH; M=C, oxygen, N, and R.sub.3 is C.sub.0 -C.sub.10 alkyl substituted aryl; wherein Z is as defined in (2iv) above and R.sub.3 is C.sub.0 -C.sub.10 alkylsubstituted aryl wherein "substituted aryl" is as defined above.; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together forming another aryl group; and X is hydrogen, halo, alkyl, alkoxy, hydroxy, nitro, amino, trifluoromethyl and aryl, to a patient in need of such inhibition such as hypotension, inflammtion, autoimmune diseases, and septic shock and the like.
摘要:
The present invention provides novel protein tyrosine phosphatase modulating compounds having an aryl acrylic acid structure, compositions comprising the compounds, and methods of making and using the same.